Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

BACKGROUND: Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-week, placebo-controlled, randomized period of the Phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Raghu, Ganesh, Hamblin, Mark J., Brown, A. Whitney, Golden, Jeffrey A., Ho, Lawrence A., Wijsenbeek, Marlies S., Vasakova, Martina, Pesci, Alberto, Antin-Ozerkis, Danielle E., Meyer, Keith C., Kreuter, Michael, Burgess, Tracy, Kamath, Nikhil, Donaldson, Francis, Richeldi, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123757/
https://www.ncbi.nlm.nih.gov/pubmed/35597980
http://dx.doi.org/10.1186/s12931-022-02047-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123757/
https://www.ncbi.nlm.nih.gov/pubmed/35597980
http://dx.doi.org/10.1186/s12931-022-02047-0

Ejemplares similares